DAKAR, Senegal – Congo has approved the use of four more experimental treatments for the outbreak of the Ebola virus in the Northeast, because health officials are trying to stop the spread amidst the threat of armed groups in the region.
The treatments ZMapp, Remdesivir, Favipiravir and Regn3450 – 3471 – 3479 can now be used in people suffering from Ebola, the Department of Health said Wednesday. Tuesday, health officials have delivered Remdesivir, produced by Gilead Sciences, to a patient in Beni, the ministry said.
Health officials began on 11 August on 10 patients with the mAb114 treatment and the ministry said they were doing well.
The tenth Ebola outbreak in Congo was declared in Mangina in the province of North Kivu on 1 August. So far there are 75 confirmed Ebola cases and 27 probable cases. Of the 59 deaths, 32 have been confirmed as Ebola, according to the Ministry of Health.
More than 1,600 people have been vaccinated since 8 August in Mabalako and Beni in the province of North Kivu and in Mandima in the province of Ituri, according to the ministry.
Insecurity in the region, especially in what the World Health Organization calls "red zones", where several armed groups are carrying out attacks, hinders efforts to treat everyone.
North Kivu is densely populated with more than 1 million displaced people. According to health officials, the local population in the vicinity of the heavily traveled border with Uganda is not familiar with the disease, so the range is important.
Ebola is spread through contact with body fluids of infected people, including the dead, and can be deadly in 90 percent of cases, depending on the species.
Follow the news from Africa at https://twitter.com/AP_Africa
Copyright 2018 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.